Gilead-Backed Aspen Neuroscience Shares Decline 2% After US IPO
Aspen Neuroscience Inc., a clinical-stage developer of cell therapies, fell 2% after raising about $140.6 million in a US initial public offering.
By Angel Adegbesan ยท Bloomberg Markets
Aspen Neuroscience Inc., a clinical-stage developer of cell therapies, fell 2% after raising about $140.6 million in a US initial public offering.